Puma sinks as neratinib NDA delayed almost one year
This article was originally published in Scrip
Executive Summary
Puma Biotechnology's stock fell 18.4% in after-hours trading to $183.60 per share on 2 December following the company's disclosure that its new drug application (NDA) for neratinib in the adjuvant treatment of breast cancer will be delayed by almost a year.